Cargando…

The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults

Nontuberculous mycobacteria (NTM) can cause and perpetuate chronic inflammation and lung infection. Despite having the diagnostic criteria, as defined by the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA), clinicians find it challenging to diagnose and treat NTM-in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Omer, Chaudary, Nauman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293904/ https://www.ncbi.nlm.nih.gov/pubmed/32606598 http://dx.doi.org/10.2147/DDDT.S146111

Ejemplares similares

Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
por: Rubino, Christopher M., et al.
Publicado: (2021)

Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease
por: Rubino, Christopher M., et al.
Publicado: (2021)

Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages
por: Zhang, Jimin, et al.
Publicado: (2018)

Liposomal Amikacin Inhalation Suspension-induced Pneumonitis
por: Kidogawa, Moe, et al.
Publicado: (2022)

Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
por: Hoy, Sheridan M.
Publicado: (2021)

Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease
por: Marras, Theodore K., et al.
Publicado: (2022)

Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
por: Hoy, Sheridan M.
Publicado: (2021)

Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
por: Shirley, Matt
Publicado: (2019)

Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
por: Shirley, Matt
Publicado: (2019)

Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience
por: Chiron, Raphael, et al.
Publicado: (2022)

805. Amikacin Liposome Inhalation Suspension (ALIS) Add-on Therapy for Refractory Mycobacterium avium Complex (MAC) Lung Disease: Effect of In Vitro Amikacin Susceptibility on Sputum Culture Conversion
por: Brown-Elliott, Barbara A, et al.
Publicado: (2018)

Laryngitis after inhalation of liposomal amikacin
por: Morita, Atsuho, et al.
Publicado: (2022)

Diagnosis and Management of Drug-Induced Interstitial Lung Disease Associated with Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium Avium Complex Pulmonary Disease: A Case Report
por: Hashimoto, Kazuki, et al.
Publicado: (2023)

Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study
por: Henriette Zweijpfenning, Sanne Maria, et al.
Publicado: (2022)

Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada
por: Aznar, Maria Luisa, et al.
Publicado: (2019)

Population Pharmacokinetic Analysis of Amikacin for Optimal Pharmacotherapy in Korean Patients with Nontuberculous Mycobacterial Pulmonary Disease
por: Jin, Xuanyou, et al.
Publicado: (2020)

Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial
por: Winthrop, Kevin L., et al.
Publicado: (2021)

Clinical Management of Respiratory Adverse Events Associated With Amikacin Liposome Inhalation Suspension: Results From a Patient Survey
por: Swenson, Colin, et al.
Publicado: (2020)

The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases
por: Yagi, Kazuma, et al.
Publicado: (2017)

Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Mycobacterium avium Complex Lung Disease in Real-World Settings
por: Morita, Atsuho, et al.
Publicado: (2022)

Delivery of Aerosolized Liposomal Amikacin as a Novel Approach for the Treatment of Nontuberculous Mycobacteria in an Experimental Model of Pulmonary Infection
por: Rose, Sasha J., et al.
Publicado: (2014)

Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease
por: Kwon, Yong-Soo, et al.
Publicado: (2016)

Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections
por: Chalmers, James D., et al.
Publicado: (2021)

Positive Effect of Liposomal Amikacin for Inhalation on Mycobacterium abcessus in Cystic Fibrosis Patients
por: Caimmi, Davide, et al.
Publicado: (2018)

Nontuberculous mycobacterial osteomyelitis
por: Bi, Sheng, et al.
Publicado: (2015)

Recent advances in nontuberculous mycobacterial lung infections
por: Horne, David, et al.
Publicado: (2019)

The lung microbiota in nontuberculous mycobacterial pulmonary disease
por: Kim, Bo-Guen, et al.
Publicado: (2023)

Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies
por: Rocco, Joseph M., et al.
Publicado: (2021)

The Impact of Nontuberculous Mycobacteria Species on Mortality in Patients With Nontuberculous Mycobacterial Lung Disease
por: Wang, Ping-Huai, et al.
Publicado: (2022)

Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings
por: Aksamit, Timothy, et al.
Publicado: (2022)

Treatment of Extrapulmonary Nontuberculous Mycobacterial Diseases
por: Wi, Yu Mi
Publicado: (2019)

Molecular assessment of mycobacterial burden in the treatment of nontuberculous mycobacterial disease
por: Ellis, Huw C., et al.
Publicado: (2023)

Recurrent Nontuberculous Mycobacterial Tenosynovitis
por: Kwan, Melissa, et al.
Publicado: (2021)

Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease: Clinicians' Perspectives
por: Ryu, Yon Ju, et al.
Publicado: (2016)

Infection Source and Epidemiology of Nontuberculous Mycobacterial Lung Disease
por: Jeon, Doosoo
Publicado: (2019)

Profiling mycobacterial communities in pulmonary nontuberculous mycobacterial disease
por: Cowman, Steven A., et al.
Publicado: (2018)

Pulmonary Deposition and Elimination of Liposomal Amikacin for Inhalation and Effect on Macrophage Function after Administration in Rats
por: Malinin, Vladimir, et al.
Publicado: (2016)

Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease
por: Kang, Hyung Koo, et al.
Publicado: (2015)

Diagnosis of Pulmonary Tuberculosis and Nontuberculous Mycobacterial Lung Disease in Korea
por: Kwon, Yong Soo, et al.
Publicado: (2014)

Epidemiology of Nontuberculous Mycobacterial Lung Disease and Tuberculosis, Hawaii, USA
por: Adjemian, Jennifer, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dlli69vm9kskedkgrrgt0nhtot